Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Matt Labenski, PhD (he/him/his)

Jnana Therapeutics, Massachusetts, United States

Matt Labenski is the Senior Director of Proteomics and Chemical Biology at the Boston-based biotech Jnana Therapeutics. While at Jnana he co-invented a ligand discovery technology called RAPID, which is a novel chemoproteomics platform that enables the identification of lead-like small molecule binders to any target of interest inside of a living cell. Jnana is leveraging RAPID to unlock historically difficult-to-drug targets, including the solute carrier (SLC) family of metabolite transporters, transcription factors, and phosphatases. Prior to Jnana, Matt worked at Avila Therapeutics where he built the chemoproteomics and covalent warhead reactivity platforms to evaluate targeted covalent inhibitors of kinases. He then moved on to work in the biochemistry group at Celgene where he built several clinical biomarker assays, used chemoproteomics to understand small molecule interaction with protein targets, and used the mass spec to help solve a variety of drug discovery-related issues. Matt obtained his PhD in pharmacology and toxicology at the University of Arizona under the mentorship of Serrine Lau.

Disclosure information not submitted.

Presentation(s):